Suven Life Sciences Ltd
has announced the grant of two product patents from Australia and one product patent from Singapore. "The orders/ correspond to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034," the company said in a filing to the exchanges on Thursday.
The granted claims of the patents include the class of selective H3 Inverse agonists and 5HT6 compounds, respectively. They are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders. These include Alzheimer’s, attention-deficit hyperactivity disorder (ADHD), Huntington’s disease, narcolepsy, Parkinson's, and Schizophrenia.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Suven CEO Venkat Jasti said.
Suven Life Sciences, a biopharmaceutical, is majorly into the business of CRAMS (contract research and manufacturing services). In FY17, it derived 64% of revenue from CRAMS, 23.5% from specialty chemical, and 12.5% from technical services including royalties.
Suven Life Sciences ended the day at Rs186.65, down Rs5.05, or 2.63%, from its previous close of Rs191.70 on the BSE.